Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction on adriamycin-induced nephropathy in rats

Chin J Integr Med. 2012 Aug;18(8):591-8. doi: 10.1007/s11655-011-0816-x. Epub 2011 Jul 30.

Abstract

Objective: To investigate the antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction (, MDBD) on adraimycin-induced nephropathy in rats.

Methods: Thirty-two male Sprague Dawley albino rats were randomly divided into 4 groups: the control, model, and two treatment groups, with 8 in each group. Nephropathy was induced in the latter 3 groups by intravenous injection of adriamycin. Rats in the two treatment groups received intragastric administration of benazepri (a positive control) or MDBD, which is composed of extracts of Radix Angelicae sinensis, Astragalus membranaceus (Fisch.) Bge and Rhizoma chuanxiong. Serum albumin, blood lipids, 24-h urine protein and urine N-acetyl-b-D-glucosaminidase (NAG) were measured every 2 weeks. The ratio of kidney to body weight was measured. The expressions of extracellular matrix proteins in the renal cortex, including colleagen IV (Col-IV) and fibronectin (FN), were examined by immunohistochemistry, and the transcription of genes encoding transforming growth factor β1 (TGF-β1), the tissue inhibitors of matrix metalloproteinase 1 (TIMP-1) and matrix metalloproteinase 9 (MMP-9) were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) at the end of the 8-week treatment.

Results: Compared with the untreated rats in the model group, MDBD significantly increased serum albumin, lowered the blood lipids and decreased the ratio of kidney to body weight. MDBD significantly reduced the excretion levels of urinary protein and NAG as well as the accumulation of extracellular matrix (ECM), including Col-IV and FN, in the renal cortex. Further, MDBD decreased TIMP-1 and TGF-β1 gene expressions and increased MMP-9 gene expression in the kidney.

Conclusions: MDBD was effective in treating the rat model of nephropathy. The clinical benefit was associated with reduction of renal fibrosis. The antifibrotic effect of MDBD may be mediated through the regulation of TIMP-1, MMP and TGF-β1 gene expressions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylglucosaminidase / urine
  • Animals
  • Body Weight / drug effects
  • Collagen Type IV / metabolism
  • Doxorubicin
  • Drugs, Chinese Herbal / pharmacology
  • Drugs, Chinese Herbal / therapeutic use*
  • Fibronectins / metabolism
  • Fibrosis
  • Gene Expression Regulation / drug effects
  • Immunohistochemistry
  • Kidney Cortex / drug effects
  • Kidney Cortex / enzymology
  • Kidney Cortex / pathology
  • Kidney Cortex / physiopathology
  • Kidney Diseases / blood
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / physiopathology
  • Kidney Diseases / urine
  • Kidney Function Tests
  • Male
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism
  • Organ Size / drug effects
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Serum Albumin / metabolism
  • Time Factors
  • Tissue Inhibitor of Metalloproteinase-1 / genetics
  • Tissue Inhibitor of Metalloproteinase-1 / metabolism
  • Tissue Inhibitor of Metalloproteinase-2 / genetics
  • Tissue Inhibitor of Metalloproteinase-2 / metabolism
  • Transforming Growth Factor beta1 / genetics
  • Transforming Growth Factor beta1 / metabolism
  • Triglycerides / blood

Substances

  • Collagen Type IV
  • Drugs, Chinese Herbal
  • Fibronectins
  • RNA, Messenger
  • Serum Albumin
  • Tissue Inhibitor of Metalloproteinase-1
  • Transforming Growth Factor beta1
  • Triglycerides
  • danggui buxue decoction
  • Tissue Inhibitor of Metalloproteinase-2
  • Doxorubicin
  • Acetylglucosaminidase
  • Matrix Metalloproteinase 9